Skip to content

Canceled by the investigator Accurate localization of individualized transcranial magnetic stimulation based on resting state functional magnetic resonance in the treatment of depression

Accurate localization of individualized transcranial magnetic stimulation based on resting state functional magnetic resonance in the treatment of depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057358
Enrollment
Unknown
Registered
2022-03-09
Start date
2022-03-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MDD

Interventions

FC-guided target:iTBS
Classic coordinate target:iTBS

Sponsors

The first hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet DSM-V diagnostic criteria for depression and are diagnosed with severe depressive episode; 2. HAMD>17 points (Melzer et al., 2012); Chinese version of Mood Disorder Questionnaire (MDQ)<7 points; 3. Concise International Psychiatric Interview 7.0.0 (M.I.N.I.7.0.0) was used to confirm that the subject was currently suffering from depression; 4. Gender unlimited, age 20-55; 5. Subjects who can understand and are willing to strictly abide by the clinical trial protocol to complete the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Magnetic resonance and TMS contraindications; 2. Serious heart, liver and kidney diseases, no thyroid, tumor, blood history, rheumatism, malnutrition, nervous system and other diseases; 3. Schizophrenia, bipolar disorder, history of abuse of tobacco, alcohol and other psychoactive substances; 4. High risk of suicide; 5. The patient is a pregnant or lactating woman or a planned pregnancy; 6. Not taking immunomodulator and hormone preparations for at least half a year, and not taking antipyretic and analgesic drugs for 2 weeks; 7. The researcher thinks it is not suitable to be included.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale,HAMD;

Secondary

MeasureTime frame
Hamilton Anxiety Scale,HAMA;Self-rating depression scale,SDS;Self-rating anxiety scale,SAS;The Insomnia Severity index,ISI;Beck Scale for Suicide Ideation-Chinese Version, BSI-CV;Visual Analogue Score, VAS;Clinical Global Impression, CGI;Snaith-Hamilton Pleasure Scale, SHAPS;

Countries

China

Contacts

Public ContactWang Yumei

Hebei Provincial People's Hospital

wangyumei19771021@hotmail.com+86 18633889983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026